Last results 21 Jul 2026
Novartis AG ADR
I · AI Analysis
The brief
Novartis develops and sells prescription medicines across cardiovascular disease (Entresto for heart failure), immunology (Cosentyx for psoriasis and arthritis), oncology (Pluvicto for prostate cancer, Kisqali for breast cancer), and rare diseases (Zolgensma for spinal muscular atrophy) [Yahoo Finance]. The company operates globally, manufacturing drugs in multiple countries and selling through hospitals, clinics, and specialty pharmacies [Yahoo Finance].
Novartis is a Swiss pharmaceutical giant with over 75,000 employees making drugs for heart disease, cancer, immune disorders, and rare genetic conditions [Yahoo Finance]. The company posted $54.8B in revenue with strong margins (75% gross, 32% operating) and solid cash generation ($17.7B free cash flow), reflecting a diversified portfolio of branded medicines [Yahoo Finance]. Recent positive clinical trial results for Pluvicto, a radioactive cancer therapy, have driven modest stock gains and positioned Novartis as a leader in an emerging treatment category [Simply Wall St].
Novartis is financially healthy with strong profitability, low leverage, and consistent cash generation [Yahoo Finance].
Sentinellis health
8.9/10
Financially healthy
Market capitalisation
$287.1B
Revenue (TTM)
$54.8B
Explainers
How we read these numbers
Plain-English guides · no account needed
ROIC vs WACC Explained: How to Tell If a Company Actually Creates Value
What ROIC and WACC are, how to compute both, and why the spread between them is the single most important number in fundamental investing.
ReadPiotroski F-Score Explained: A 9-Point Financial Health Check (with a Live Apple Example)
What the Piotroski F-Score is, how to calculate all 9 criteria, and how to read the result. Plain English, with a real Apple walkthrough.
ReadAltman Z-Score Explained: Predicting Bankruptcy in 5 Minutes (with Real Examples)
What the Altman Z-Score is, the exact formula, how to read the result, and which version to use for manufacturers vs tech vs private companies.
ReadII · Recent news
What moved
6 stories · ranked by relevance
- Macro2026-05-20
Novartis (SWX:NOVN) Valuation Check After New Pluvicto PSMAddition Study Data And Regulatory Filings
Simply Wall St
- Macro2026-05-18
Hepatic Cirrhosis Market Research and Forecast Report 2026-2036, Profiles of Abbott, Astellas Pharma, Gilead Sciences, Novartis, Takeda Pharma, Grifols Therapeutics, and Cellaion
Yahoo Finance
- Macro2026-05-18
Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC
Nasdaq
- Macro2026-05-14
Novartis Expands US Radioligand Network And Manufacturing For Future Growth
Simply Wall St
- Macro2026-05-17
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Yahoo Finance
- Macro2026-05-14
Interleukin-6 (IL-6) Receptor Antagonists and IL6- Inhibitors Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Antagonists and Inhibitors by Drug Modality
Yahoo Finance
Premium · Free with any account
Patent expirations on blockbuster drugs will eventually erode revenue unless the pipeline delivers replacements — a structural risk in pharmaceutical business models [Yahoo Finance]
Risks
4
Opportunities
5
Red flags
2
Leadership
10
10 more findings in the full report — free with any account.
Unlock the full Novartis AG ADR analysis
Create a free account to access the complete AI-generated report with inline citations.
- 4 risks, 5 opportunities and 2 red flags — each with its source
- 100+ financial metrics with charts and benchmarks
- Full news summaries with source links
- Executive team and compensation details
- PDF export for offline use
III · Related
You might also read
Same sector · Healthcare — or comparable health
Want this for your watchlist?